These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39182542)

  • 1. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A; Goyal A
    Eur J Pharmacol; 2024 Nov; 982():176936. PubMed ID: 39182542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO; Glotfelty EJ; Li Y; Greig NH
    Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
    Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
    Kopp KO; Li Y; Glotfelty EJ; Tweedie D; Greig NH
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.
    Monney M; Jornayvaz FR; Gariani K
    Diabetes Metab; 2023 Sep; 49(5):101470. PubMed ID: 37657738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R; Almutairi M; Ussher JR
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
    Chen SD; Chuang YC; Lin TK; Yang JL
    Eur J Pharmacol; 2023 Jan; 938():175439. PubMed ID: 36470445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X; Feng P; Ji R; Ren Y; Wei W; Hölscher C
    Expert Opin Ther Targets; 2022 May; 26(5):445-460. PubMed ID: 35584372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C
    Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D; Lv G
    Peptides; 2018 Mar; 101():89-94. PubMed ID: 29329976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C
    Br J Pharmacol; 2022 Feb; 179(4):695-714. PubMed ID: 33900631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D; Foltynie T
    Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
    J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F; Moretti A; Villa RF
    Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.